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Highlights 
• Hepatitis D virus (HDV) infection is common among HBsAg positive people 
worldwide  
• Among HBsAg-positive people, estimated HDV prevalence is 4.5% (95% CI 3.6, 5.7)  
• HDV prevalence in HBsAg-positive hepatology clinic attendees is 16.4% (14.6, 18.6) 
• HDV prevalence is higher in people who inject drugs and who have hepatitis C or HIV 
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Background and Aims 
There are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection 
and its contribution to the burden of liver disease. We estimated the global prevalence of 
HDV infection and explored its contribution to the development of cirrhosis and 
hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people. 
 
Methods 
We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV 
among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed 
model, weighting for study quality and population size. The population attributable fraction 
(PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using 
random-effects models.  
 
Results 
We included 282 studies, comprising 376 population samples from 95 countries, which 
together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV 
prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 
18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the 
general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV 
positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of 
Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, 
haemodialysis recipients, men who have sex with men, commercial sex workers, and those 
with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of 
HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC. 
 
Conclusions 
An estimated 12 million people worldwide have experienced HDV infection, with higher 
prevalence in certain geographic areas and populations. HDV is a significant contributor to 




We combined all available studies to estimate how many people with hepatitis B also have 
hepatitis D, a virus infection that only affects people with hepatitis B. About 1 in 22 people 
with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver 
disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of 
liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to 











Globally, chronic infection with the hepatitis B virus (HBV) is an important cause of liver-
related morbidity and mortality due to its widespread distribution. An estimated 257 to 291 
million people are  chronically infected with HBV and are at risk of cirrhosis and 
hepatocellular carcinoma (HCC).
1, 2
 The proportion of cirrhosis attributable to HBV varies 
geographically according to HBV epidemiology, ranging from 6% in North America, to 6-21% 
in Latin America, 34-38% in Sub-Saharan Africa, and 39% in East Asia.
3
 Worldwide, HBV is 




Hepatitis D virus (HDV) is a satellite RNA virus that depends on HBV for propagation.
5
 It uses 
the hepatitis B surface antigen (HBsAg) as a viral envelope and shares the same hepatocyte 
receptor for viral entry.
6
 HDV is among the smallest of viruses capable of causing human 
disease, yet HBV co-infection with HDV is the most severe form of viral hepatitis.
5
 HDV 
transmission follows two patterns. Infection occurring simultaneously with HBV can cause 
extensive hepatic necrosis and manifest as a severe or even fulminant hepatitis with a high 
case fatality rate.
6
 With recovery, simultaneous infection in adults usually results in 
clearance of both viruses.
5
 Super-infection of persons with chronic HBV infection typically 
results in HDV persistence, leading to accelerated progression to cirrhosis and an increased 
risk of HCC relative to chronic HBV infection alone.
7
 Due to variation in awareness and 
incomplete testing among HBsAg positive people
8
, issues with standardisation of 
confirmatory molecular diagnostic techniques
9
, and a historical lack of effective treatment 
options,
10
 HDV ascertainment has been suboptimal, even in high-income settings. HDV may 
therefore have an under-recognised role in the causation of liver disease and liver-related 
deaths. 
 
Estimating HDV prevalence and the relative contribution of HDV towards liver disease, 
including among general populations and specific population groups, is critical to guide 
clinical care and policy formulation and inform effective public health interventions and 
development of new medicines. Yet, obtaining accurate estimates of HDV epidemiology is 
challenging for several reasons. Firstly, at the population level, large sample sizes are 
required to identify HBsAg-positive individuals prior to testing for HDV. In settings with low 
prevalence of HBV infection, sufficiently large surveys may not be feasible. Secondly, 
heterogeneity in HDV estimates might be expected as a result of variable and potentially 
evolving epidemic patterns, as well as due to variations in methodology. Thirdly, the 
selection criteria for HBsAg and subsequent HDV testing may lead to non-representative 
sampling. Therefore, careful assessment of potential biases and assessment of 
representativeness is required to synthesise epidemiological estimates of HDV prevalence.  
 
In a previous review, we identified foci of HDV endemicity in sub-Saharan Africa.
11
 This 
systematic review and meta-analysis aimed to identify and collate all globally available 




describe the geographic distribution of HDV infection and to produce regional estimates of 
HDV infection among general populations, individuals attending hepatology clinics, and 
selected population groups, being mindful of potential sources of error. We further aimed 
to estimate the proportion of HBV-associated cirrhosis and HCC attributable to HDV.  
 
Methods 
Outcomes of the analysis 
We performed a systematic review and meta-analysis of HDV prevalence in the six WHO 
regions. The primary outcome was the prevalence of total or IgG anti-HDV among HBsAg-
positive people.  The prevalence of HDV RNA detection was estimated among individuals 
positive for HBsAg and anti-HDV based on assays employing polymerase chain reaction 
(PCR). The secondary outcome was the estimation of the population attributable fraction 
(PAF) of HDV among HBsAg-positive persons with cirrhosis and HCC. We conducted the 
study in accordance with the principles of the PRISMA and GATHER statements, and 
registered it with PROSPERO (CRD42018113039). 
 
Search method 
We searched PubMed, EMBASE and Scopus on 17
th
 April 2018 for articles published since 1 
January 1998 and repeated the search on 28
 
January 2019. The search strategy included 
synonyms of hepatitis D and terms describing HDV epidemiology and diagnosis (detailed in 
Supplementary Appendix 1). We included all languages. Articles in eight languages unknown 




 February 2019, we 
also performed searches of the grey literature within the Global Health Data Exchange 
database, international health surveillance programmes, and official national health 
surveillance websites (listed in Supplementary Appendix 2), and reviewed surveys, censuses, 
vital statistics, and reports not already included in previously identified scientific 
publications. We contacted 21 corresponding authors to seek clarifications on their 
published data. We additionally searched GenBank 
(https://www.ncbi.nlm.nih.gov/genbank/) and the European Nucleotide Archive 
(http://www.ebi.ac.uk/ena) to retrieve HDV sequences and genotypes.  
 
Inclusion and exclusion criteria 
We included studies that described the geographic and clinical setting of participants with 
HBsAg and applied a systematic selection method to anti-HDV testing, whereby all eligible 
consenting participants, or a randomly selected representative sample were tested. 
Duplicate data, studies that commenced before 1988, and studies with evidence of selective 
or non-systematic testing were excluded. Studies were also excluded if they used anti-HDV 
IgM, hepatitis D antigen (HDAg) or HDV RNA as an initial test  as these are inconsistently 
expressed markers of HDV infection.
12
 Studies that focussed on the following groups were 
excluded: individuals with acute hepatitis, returning (repeat) or remunerated blood donors, 




the country of destination, children <18 months who may have maternal anti-HDV transfer, 
and liver transplant registers or recipients, due to the variability of selection criteria. 
Included studies are referenced in Supplementary Appendices 3-6. 
 
Data extraction and assessment of study quality 
Following removal of duplicate articles, two authors (AJS and BK) independently screened 
potentially relevant articles to determine suitability for inclusion. We extracted data 
comprising year of sampling, geographic representation of the sample (for example, a 
catchment area of a clinic or the geographic boundaries of a community study), population 
type, clinical setting, testing method and assay manufacturer, anti-HDV and HDV RNA 
prevalence, and HDV genotype data. We derived a data quality score from an appraisal 
checklist (detailed in Supplementary Appendix 7) customized from two previously published 
quality assessment tools for prevalence studies.
13, 14
 The assessment was based on three 
main criteria relating to i) adequacy of description of inclusion and exclusion criteria; ii) 
recruitment methodology; and iii) assessment of risk of bias. Determination of eligibility for 
inclusion, data extraction and risk of bias were assessed independently (by AJS and BK) with 
disagreement resolved by consensus.  
 
Statistical methods 
Anti-HDV prevalence was described among three groups: i) general populations, comprising 
people tested in community surveys, antenatal clinics, or occupational settings, students, 
and blood donors (unless repeat or remunerated); ii) hepatology clinic populations, 
comprising patients reviewed in a hepatology service, regardless of disease status; and iii) 
selected population groups, comprising people who inject drugs (PWID), haemodialysis 
recipients, men who have sex with men (MSM), commercial sex workers (CSW), and people 
with hepatitis C virus (HCV) or HIV. In sub-Saharan African countries with generalised HIV 
epidemics (adult prevalence >1% based on UNAIDS estimates, https://aidsinfo.unaids.org/) 
people with HIV were included in the general population (note: we previously documented 
a lack of association between HIV status and anti-HDV prevalence in this setting).
11
 The 
definition of general populations excluded isolated or remote communities to avoid biasing 
the general estimates. 
 
Anti-HDV prevalence among HBsAg-positive people within general populations and 
hepatology clinic populations was modelled using a binomial mixed model (detailed in 
Supplementary Appendix 8). The estimates were weighted by the data quality score 
described above (Supplementary Appendix 7) and the size of the represented population. 
For each population, the size of the catchment area was estimated from the latest available 
census data (detailed in Supplementary Appendix 9).
15
 For nationally representative surveys,  
United Nations Population Division population estimates for 2018 were used.
16
 To predict 
anti-HDV prevalence in the overall population (without conditioning on HBsAg status), we 
used WHO HBsAg prevalence estimates for general populations
17




intervals (CIs) for the number of people with anti-HDV and HDV RNA was estimated using a 
parametric bootstrap procedure (Supplementary Appendix 8). Heterogeneity across 
populations and between samples (individual data points) was accounted for by the 
introduction of an explicit covariate and by the random effects model (Supplementary 
Appendix 8).  
 
To evaluate the association between anti-HDV prevalence and selected population groups, 
odds ratios (OR) were pooled using a random effects model. For studies that did not report 
a comparable control population, the comparator was drawn from the highest quality 
available dataset that had been obtained from either the general population or 
asymptomatic HBsAg-positive people in the same geographic region. Asymptomatic HBsAg-
positive people were defined as patients who had been clinically evaluated and found not to 
have evidence of active chronic hepatitis, cirrhosis or HCC. In the analysis of HIV-positive 
people, comparator populations were HIV-negative populations or general populations from 
the same geographic region. Subgroup estimates, stratified by the type of control 





 to estimate heterogeneity where I
2
 represents the proportion of 
variability that could be attributed to heterogeneity and not sampling error and τ
2 
represents an estimate of between-study variance, for each group.  
 
We estimated prevalence of HDV RNA among people with anti-HDV using a random effects 
model and analysed associations between study characteristics and rates of HDV RNA 
detection using random effects residual maximum likelihood aggregate level meta-
regression with Knapp and Hartung adjustment, using the package metareg in Stata. 
Coefficients were calculated to indicate the change in proportion of HDV RNA per unit 
change in explanatory variable, where for example, a coefficient of 0.1 indicates a 10% 
increase in HDV RNA detection per unit increase in the explanatory variable. 
 
To facilitate interpretation of anti-HDV prevalence estimates among patients diagnosed with 
cirrhosis or HCC, we calculated the PAF of HDV for cirrhosis and HCC among HBsAg-positive 
people. We used methodology recommended by the WHO, where PAF = prevalence among 
cases* [(odds ratio- 1)/ odds ratio].
18, 19
 where odds ratio (OR) is used as an approximation 
for the disease risk ratio of exposed (anti-HDV positive) vs nonexposed (anti-HDV negative) 
participants. The odd ratio calculation included HBsAg positive general populations or 
asymptomatic HBsAg positive people (as defined above), using empirical data from the 
highest quality and largest sample available from the same geographic region as the control 
population.
3, 4, 20
  We used a parametric bootstrap method to estimate confidence 
intervals for the PAF for each study, and simulated anti-HDV prevalence in cases and 
controls using a binomial distribution. We estimated pooled PAF using a DerSimonian-Laird 








Analyses were performed in ArcGIS Pro 2.0 (ESRI, Redland, CA, USA), Stata 16.0 (College 





A search of PubMed, Embase, and Scopus identified 2,104 articles published between 1 
January 1998 and 28
th
 January 2019, after removal of duplicate citations. Following a review 
of abstracts, we selected 745 articles for review of full text (Figure 1). We identified 329 
reports for review in the grey literature, and none was eligible for inclusion, mainly due to 
selection bias or incomplete reporting. We included 282 studies, reporting data from 376 
unique population samples from 95 countries.  
 
Data availability 
Overall, across 6 WHO regions, 155 samples were from general populations, 137 were from 
hepatology clinics, and 84 were from selected population groups (Figure 2, Supplementary 
Appendix 10). We excluded from general population estimates 19 studies that sampled 
isolated island or remote indigenous communities (Supplementary Appendix 11). Repeated 
longitudinal testing of the same population was reported from 12 samples. Overall, 120,293 
HBsAg-positive individuals were tested for anti-HDV using various assays (Supplementary 
Appendix 12); in 12.7% of the studies, the anti-HDV testing method was not specified. 
Overall, 5,065 anti-HDV positive participants were tested for HDV RNA (Figure 3). 
 
Anti-HDV prevalence in general populations and hepatology clinic populations 
In the general population, the global estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 
5.7) among HBsAg-positive people and 0.16% (95% CI 0.11, 0.25) overall, with regional 
estimates for HBsAg-positive people ranging from 3.0% in Europe to 6.0% in Africa (Table 1). 
This represents an estimated 12.0 million HDV seropositive individuals globally (95% CI 8.7, 
18.7). In hepatology clinic populations, the global estimated anti-HDV prevalence was 16.4% 
(95% CI 14.6, 18.6) among HBsAg-positive people, with estimates ranging from 3.3% in the 
Americas to 19.5% in Europe (Table 1). Country-level estimates for general populations and 
hepatology clinic populations are shown in Figure 4 and are detailed in Supplementary 
Appendix 13. Among HBsAg-positive people, Mongolia had the highest national anti-HDV 
prevalence (36.9%); prevalence rates >10% were also estimated for the Republic of Moldova 
and countries in Western and Middle Africa. Several isolated communities were noted to 
have high HDV anti-prevalence, including indigenous Amazonian Amerindian tribes in 
Bolivia, Brazil, Colombia and Venezuela, indigenous tribes in the Uttar Pradesh region of 
India, and selected populations in Greenland and Rhodes (Greece) (Figure 3, Supplementary 
Appendix 11). Only limited data were available for North America, Latin America and 




were small samples available for the Western Pacific and South-East Asia regions relative to 
other WHO regions (Figure 2 and 3). 
 
Anti-HDV prevalence in selected population groups 
The odds of anti-HDV detection were analysed in six selected populations relative to general 
populations or asymptomatic HBsAg-positive people from the same geographic region 
(Figure 6 and Supplementary Appendices 14-20). Anti-HDV prevalence was higher in PWID 
(pooled OR 19.0) and in haemodialysis recipients (pooled OR 3.4). Five studies from China 
and Vietnam indicated that CSWs also had higher prevalence (pooled OR 18.7). Three 
studies from Italy, Burkina Faso and Indonesia investigated anti-HDV prevalence among 
MSM. No cases were reported in the Burkina Faso study, whereas data from the other two 
studies indicated that anti-HDV prevalence was higher among MSM (pooled OR 16.0). The 
odds of anti-HDV detection were also higher among anti-HCV positive people (pooled OR 
10.0) and among HIV-positive people in countries without generalised HIV epidemics 
(pooled OR 6.6). In countries with generalised HIV epidemics, the odds of anti-HDV 
detection were similar in HIV-positive and HIV-negative people (pooled OR 0.8). 
 
HDV RNA detection and HDV genotypes   
HDV RNA was tested in 5073 anti-HDV positive people. The pooled proportion with HDV 
RNA detection was 58.5% (95% CI 52.4, 64.5) (Supplementary Appendix 21). Overall, HDV 
RNA prevalence correlated with anti-HDV prevalence, with a co-efficient of 0.03 (95% CI 
0.02, 0.06; p<0.0001) indicating a 3% increase in HDV RNA detection per each 10% increase 
in anti-HDV prevalence. HDV RNA detection was lower in general populations relative to 
hepatology clinic populations (co-efficient -0.20; 95% CI -0.33, -0.07; p=0.003). There was 
also lower HDV RNA detection in the African region compared to other WHO regions (41.3% 
versus 64.9%; co-efficient -0.13; 95% CI -0.26, -0.002; p=0.05). Subject to the limitations of 
the available data, a preliminary estimate of 7.1 million people (95% CI 5.0, 11.1) had 
viraemic infection (HDV RNA positive), representing a general population prevalence of 
viraemia of 0.09% (95% CI 0.07- 0.15).  
 
Searches of studies reporting HDV genotype data identified 4,159 individuals with available 
results (Supplementary Appendices 22 and 23). Genotype 1 predominated globally (89.9% 
of published data). Other genotypes were more localized, including genotype 2 in Asia, 
genotype 3 in Latin America (predominating in the Amazon basin), genotype 4 in Japan and 
China (Taiwan), genotype 5 in Western Africa, and genotypes 6-8 in Middle Africa (Figure 6). 
 
Population attributable fraction for cirrhosis and HCC among HBsAg-positive people 
Patients with cirrhosis or HCC had higher anti-HDV prevalence relative to comparator 
populations from the same geographic region, with a pooled OR of 6.7 and 4.8, respectively 
(Figure 5 and Supplementary Appendices 24 and 25). Among HBsAg-positive people with 




cirrhosis (95% CI 10, 26) and 20% of HCC (95% CI 8, 33) (Supplementary Appendices 26 and 





There has been uncertainty about the epidemic patterns of HDV infection, at least partly 
reflecting the challenges in obtaining representative estimates of anti-HDV prevalence.
24
 To 
address the issue, in this systematic review we took into account population sizes and 
representativeness and considered the risk of bias of prevalence studies. Globally, we 
estimate an anti-HDV prevalence of 4.5% among HBsAg-positive people, which translates 
into an estimated prevalence of 0.16% in the total population. This represents an estimated 
12 million people with serological evidence of HDV infection globally. The geographic 
distribution of HDV infection is heterogeneous, with particularly high prevalence reported in 
Mongolia, the Republic of Moldovia, and countries in Western and Middle Africa. We also 
identified an epidemiological association between anti-HDV prevalence and several 
population groups including PWID, recipients of haemodialysis, CSWs and MSM, and 
between anti-HDV prevalence and HCV or HIV infection, which may be secondary to shared 
transmission routes. These data are useful to set priorities about HDV testing. Interventions 
that prevent HBV and HCV infection should also be effective in preventing HDV, including 
immunization against hepatitis B and harm reduction strategies in PWID.
25-27 
 
There remain limitations to the epidemiological data available to inform this analysis. There 
are significant data gaps, most strikingly in North America and Latin America, Southern 
Africa and most of Asia, where more data are required to obtain accurate estimates of anti-
HDV prevalence. These gaps should be addressed through future representative 
epidemiological studies with efforts to elucidate population groups at increased prevalence 
of infection. There was heterogeneity in anti-HDV prevalence estimates even within closely 
related geographic areas, which is reflected in the confidence intervals for the estimates. 
Heterogeneity suggested likely variation in local risk factors and the occurrence of localised, 
geographically defined foci of transmission. Sources of heterogeneity also included 
methodological issues, such as variation in study design, inclusion and exclusion criteria and 
sampling frameworks. It should be noted that estimates in our study consider individuals 
living in regions with limited or no data for anti-HDV prevalence. To do so we calculated the 
number of people with anti-HDV in each WHO region, by multiplying the anti-HDV 
prevalence estimates for each region (based on available data) with the number of people in 
the general population estimated to be HBsAg positive (based on WHO HBsAg regional 
estimates). Collection of additional data to inform epidemiological estimates for regions 
with limited data represents a research priority. 
 
Unbiased ascertainment of anti-HDV prevalence requires large sample sizes to identify the 
subset with HBV, which poses a particular problem in regions with low HBV prevalence. In 
these regions, samples derived from settings that are enriched with HBsAg-positive people 
are often used to study anti-HDV prevalence, such as patients sampled within hepatology 
clinics. Current guidelines recommend HDV testing in selected patients with specific risk 
factors
28
 or do not explicitly recommend universal testing.
29




newly diagnosed HBsAg-positive individuals are not tested for anti-HDV as part of routine 
practice. Clinician-driven testing carries a risk of introducing an ascertainment bias. 
Specialist referral to a hepatology clinic may be the result of patients developing 
characteristics of liver disease. The resulting population may therefore be more likely to test 
anti-HDV positive and may not be fully representative of the general population. As such, to 
reduce the risk of overestimating HDV prevalence, studies based in hepatology clinic 
settings were considered separately from those of general populations. Furthermore, we 
only included samples that were representative of the target population and decided to 
exclude many laboratory-based samples or samples that relied on clinician-instigated 
testing. A previous systematic review estimated a global anti-HDV prevalence among people 
with HBsAg of 10.6%.
24
 However, as we previously noted, the analysis included data from 
sources at high risk of bias such as laboratory-based studies, analysed hepatology clinic data 
together with data from general populations, did not consider the size of the population 
represented by the included samples, and used data from small isolated communities to 
produce estimates for general populations.
24, 25
 Our study has considered each of these 
issues and as a result we estimate a lower anti-HDV prevalence among the general 
population and provide a distinct estimate for hepatology clinic populations.  
 
This study did not aim to address temporal trends in anti-HDV prevalence, as only a small 
number of studies reported repeated longitudinal data. We also found very few studies 
including children. It is anticipated anti-HDV prevalence may be low in children, due to the 
absence of specific risk factors and a short duration of risk exposure. Global estimates for 
HBV prevalence are significantly lower among children, largely as a result of HBV 
vaccination, estimated at 1.3% in children under 5 years, relative to 3.5% among the general 
population globally.
1
 Accordingly, HDV infection is expected to be uncommon in children 
and to decline over time due to increasing implementation of HBV vaccination. 
 
Due to the limitations of the available data, alongside concerns about comparability and 
standardisation of HDV RNA assays,
9
 prevalence estimates in this study were based 
primarily on detection of anti-HDV. We also provided a provisional estimate of viraemic, 
HDV RNA positive individuals. A limited number of studies used HDV RNA detection for 
confirmation of a current infection in participants with anti-HDV; in these studies, the 
pooled estimate for HDV RNA positivity was 58.5%. It is important to note that relative to 
the data available to inform anti-HDV estimates, the data for HDV RNA represent a 
significantly smaller sample size with limited representation from some regions and the 
estimate of viraemic infections should therefore be considered provisional. HDV RNA 
detection was lower in general populations relative to hepatology clinic populations, and 
positively correlated with anti-HDV prevalence. This may reflect the higher pre-test 
probability of a current HDV infection in HBsAg-positive people who underwent HDV testing 
in hepatology clinics relative to general populations. HDV RNA detection was also less 




interpreted with caution: HDV RNA assays have had historical performance issues and 
particular difficulties with the detection of African genotypes 5-8.
9
 With concerted efforts to 
improve and standardize HDV RNA detection methods, epidemiological data based on HDV 
RNA detection may become more informative in the future and also help to ascertain the 
relationship between viraemia and clinical outcomes. 
 
Furthermore, anti-HDV assays used in the included studies were from a diverse range of 
manufacturers. Comparative data on the diagnostic performance characteristics of anti-HDV 
tests are lacking and would be informative. Limited data suggests a potential for false 
negative anti-HDV ELISA test results, at least when comparing one commercial anti-HDV 
assay with a novel anti-HDV microarray test in a hyperendemic setting in Mongolia. 
26
 This 
initial finding requires verification in other regions and populations, with diverse HDV 
genotypes, and across the different anti-HDV assays available commercially to determine 
whether anti-HDV underestimation is a broader problem.  
 
Estimations of the global burden of disease from viral hepatitis have not previously 
considered HDV
30
, and HDV epidemiology and disease control are not considered in the 
current Global Health Sector Strategy for Viral Hepatitis
27
. We estimated that, globally, 
between one in five to one in six cases of cirrhosis or HCC among people with hepatitis B are 
attributable to HDV infection, indicating that hepatitis D may be an important contributor to 
liver disease. It should be noted that there was a paucity of studies reporting anti-HDV 
prevalence among people with cirrhosis and HCC from some regions (including the South-
East Asia region and the Western Pacific region), and therefore we estimated global PAFs 
and did not estimate regional PAFs. Our global PAF estimates should be considered 
preliminary until more data are made available to resolve sources of heterogeneity and 
obtain more globally representative estimates. Further, our estimates of attributable 
fraction are based on ascertainment of anti-HDV prevalence among individuals diagnosed 
with cirrhosis and HCC from cross-sectional studies. These may include individuals with early 
compensated cirrhosis. Since HDV accelerates disease progression, HDV may have an even 
greater attributable fraction of HBV-associated mortality from cirrhosis and HCC. As to the 
long-term impact of HDV RNA positivity on the risk of cirrhosis and HCC, we are limited by 
the available data, which very rarely include longitudinal follow-up to ascertain clinical 
outcomes. Ascertainment of the contribution of HDV to mortality is also not currently 
possible due to the lack of data.   
 
In summary, the data indicate that HDV infection is common among HBsAg-positive people 
in the general population worldwide, albeit with significant geographic heterogeneity. The 
data also indicate that PWID, haemodialysis recipients, CSWs and MSM, as well as people 
with HIV and HCV, are at increased odds of HDV seropositivity, and that HDV is responsible 
for a substantial proportion of cirrhosis and HCC among HBsAg-positive people. HDV 




ascertainment in clinical settings is of particular importance in view of the suppressive effect 
of HDV co-infection on HBV DNA levels,
28
 which may lead to misclassification of HBV status. 
Furthermore, novel therapeutics that target HDV entry, prenylation and nucleic acid 
replication now offer a promise of more effective treatment for HDV infection.
29-32
 If all 
people newly diagnosed with chronic HBV infection had a routine reflex test for anti-HDV, 
surveillance and ascertainment of HDV-related disease would be improved. Public health 
agencies may want to report on HDV infection and implement activities to mitigate the risk 
of HDV acquisition according to their local epidemic. In addition to the adoption of routine 
testing for all HBsAg positive people, the addition of anti-HDV/HDV RNA testing (including 
the use of dry blood spots) as part of representative population surveys such as 
demographic health surveys, would be useful in areas with sparse data.  
 
Hepatitis D is widely distributed but neglected disease. A better description of the role that 
HDV plays in causing liver disease, better efforts to improve epidemiological data collection, 
ascertainment of temporal trends and identification of locally important risk factors would 








Fig. 1. Selection of studies for inclusion in systematic review of global HDV epidemiology 
 




Fig. 3. Anti-HDV prevalence in HBsAg-positive people. (A) General populations (B) 
Hepatology clinic populations.  Each point represents a sample. Point size indicates sample 
size and colour indicates HDV seroprevalence.  
 
Fig. 4. Country-level estimates of anti-HDV prevalence among HBsAg-positive people. (A) 




Fig. 5. HDV seroprevalence among selected population groups relative to general 














































282 studies eligible for inclusion 
2104 studies identified from a search 
of PubMed, EMBASE and Scopus, 
after removal of duplicates 
1359 studies excluded after abstract review:  
316 basic science, animal or pre-clinical 
304 review, comment or editorial 
196 did not test for HDV 
160 therapeutic trial 
  99 HDV sample study 
  74 diagnostic test development  
  52 case report or case series 
  43 acute hepatitis 
  41 genotypic data only 
  24 clinical guidelines 
  17 study of migrant population only 
  16 histological studies 
    8 liver transplantation sample 
    6 mathematical modelling 
    3 duplicate data 
 
462 studies excluded after in-depth review: 
109 duplicate data 
  92 insufficient information 
  76 non-random/unrepresentative sample 
  42 review, comment or editorial 
  32 HDV sample or case-control  
  25 did not test for HDV 
  21 anti-HDV IgM, HDAg, or HDV RNA only used 
  17 genotypic data only 
  17 liver transplantation  
  16 acute hepatitis 
    6 did not test HBsAg positive people 
    6 incomparable selected risk groups  
    4 required HBV DNA detection 
    2 study of migrant population only 
    2 conducted prior to 1988 
    1 mathematical model 
 
745 studies reviewed in full and 5 
additional studies identified from 












Selected population groups comprised people who inject drugs, haemodialysis recipients, men who have sex 
with men, commercial sex workers, and people with hepatitis C virus or HIV. In sub-Saharan Africa countries 
with adult HIV prevalence >1%, HIV populations were included in the general population. Isolated populations 
were selected sample populations that were considered not representative of the general population.  
 
Abbreviations: WHO, World Health Organization; AFR, African Region; EMR, Eastern Mediterranean Region; 





Fig. 3. Anti-HDV prevalence in HBsAg-positive people. (A) General populations; (B) 
Hepatology clinic populations.  Each point represents a sample. Point size indicates 








Fig. 4. Country-level estimates of anti-HDV prevalence among HBsAg-positive people. (A) 







Fig. 5. HDV seroprevalence among selected population groups relative to general 



































Comparators are general population or asymptomatic HBsAg-positive samples from the same 
geographic region. Diamonds indicate central estimate and 95% confidence intervals (CI) for pooled 
odds ratios for each population group. I
2
 represents the proportion of variability that can be 
attributed to heterogeneity. τ
2 









 aEach circle represents a unique sample with area proportional to sample size aGenotype data 
identified by searches and from publicly available HDV sequences deposited in GenBank 





Table 1. Estimated anti-HDV prevalence in general and hepatology clinic HBsAg-positive populations, 





General Hepatology clinics 
% (95% CI) %  (95% CI) 
AFR 5.97 (4.98 - 7.24) 12.26 (10.13 - 14.70) 
AMR 5.91 (3.02 - 9.71)   3.34 (2.58 - 4.21) 
EMR 3.54 (2.10 - 6.28) 17.36 (11.15 - 26.34) 
EUR 3.00 (2.09 - 4.21) 19.48 (17.31 - 21.76) 
SEAR 3.20 (0.36 - 12.4)   4.00 (3.09 - 5.15) 
WPR 4.09 (3.47 - 4.77)   8.07 (7.50 - 8.64) 
Global 4.49 (3.57 - 5.68) 16.42 (14.58 - 18.56) 
 
Abbreviations: HBsAg, Hepatitis B surface antigen; WHO, World Health Organization; CI, Confidence 
interval; AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; 









Sources: Population data for 2018 from UN Population Division World Population Prospects 2019
16
; 




Abbreviations: WHO, World Health Organization; AFR, African Region; AMR, Region of the Americas; 
EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asian Region; WPR, 
Western Pacific Region.  
 AFR AMR EMR EUR SEAR WPR Global 
       
Population 
(thousands) 
1,052,766 1,006,458 715,425 928,490 1,982,239 1,945,717 7,631,091 
HBsAg prevalence 
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